KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Liabilities and Shareholders Equity: 2020-2024

Historic Liabilities and Shareholders Equity for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $1.4 billion.

  • Recursion Pharmaceuticals' Liabilities and Shareholders Equity rose 92.64% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 billion, marking a year-over-year increase of 101.03%. This contributed to the annual value of $1.4 billion for FY2024, which is 121.60% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Liabilities and Shareholders Equity of $1.4 billion as of FY2024, which was up 121.60% from $653.7 million recorded in FY2023.
  • Over the past 5 years, Recursion Pharmaceuticals' Liabilities and Shareholders Equity peaked at $1.4 billion during FY2024, and registered a low of $298.6 million during FY2020.
  • Over the past 3 years, Recursion Pharmaceuticals' median Liabilities and Shareholders Equity value was $701.3 million (recorded in 2022), while the average stood at $934.5 million.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Liabilities and Shareholders Equity dropped by 6.79% in 2023, and later surged by 121.60% in 2024.
  • Yearly analysis of 5 years shows Recursion Pharmaceuticals' Liabilities and Shareholders Equity stood at $298.6 million in 2020, then soared by 104.41% to $610.3 million in 2021, then grew by 14.90% to $701.3 million in 2022, then fell by 6.79% to $653.7 million in 2023, then spiked by 121.60% to $1.4 billion in 2024.